OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Transmission patterns of hepatitis E virus	177
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines	139
Editorial overview: The virome in health and disease (2022)	106
Editorial Board	79
Editorial Board	79
Editorial Board	76
Editorial Board	71
Editorial Board	63
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19	62
Editorial Board	62
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses	61
Editorial overview: Engineering elimination of chronic viral hepatitis	61
Inhaled aerosol viral-vectored vaccines against tuberculosis	60
Cryo-electron microscopy of nodavirus RNA replication organelles illuminates positive-strand RNA virus genome replication	59
Seeing and touching adenovirus: complementary approaches for understanding assembly and disassembly of a complex virion	58
Bioinformatics of virus taxonomy: foundations and tools for developing sequence-based hierarchical classification	55
Mutational escape from cellular immunity in viral hepatitis: variations on a theme	52
Alohomora! What the entry mechanisms tell us about the evolution and diversification of giant viruses and their hosts	51
The morphogenesis of different giant viruses as additional evidence for a common origin of Nucleocytoviricota	45
Editorial overview: Special issue on antiviral strategies in Current Opinion in Virology	44
Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response	43
Unresolved questions in the zoonotic transmission of MERS	42
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?	42
Gradual adaptation of animal influenza A viruses to human-type sialic acid receptors	42
Hemagglutinin stability as a key determinant of influenza A virus transmission via air	41

Host cell-intrinsic innate immune recognition of SARS-CoV-2	38
Structural insights into hepatitis C virus neutralization	37
Role of trained innate immunity against mucosal cancer	36
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity	36
Retasking of canonical antiviral factors into proviral effectors	35
Tissue-resident memory T cells in protective immunity to influenza virus	34
Test it earlier, result it faster, makes us stronger: how rapid viral diagnostics enable therapeutic success	34
Asymmetry in icosahedral viruses	33
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19	33
When good turns bad: how viruses exploit innate immunity factors	33
Immune–bacteriophage interactions in inflammatory bowel diseases	32
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities	30
Host–pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses	30
Cell-to-cell movement of plant viruses via plasmodesmata: a current perspective on potyviruses	29
Plant negative-stranded RNA virus biology and host interactions revitalized by reverse genetics	28
The enigmatic roles of Anelloviridae and Redondoviridae in humans	27
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2	27
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	27
Hepatitis B virus–host interactions and novel targets for viral cure	26
The influence of microbiota-derived metabolites on viral infections	26
Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals	25
Antivirals targeting paramyxovirus membrane fusion	25
Current challenges to virus discovery by meta-transcriptomics	24
Future considerations for the mRNA-lipid nanoparticle vaccine platform	24
Hepatitis-B virus: replication cycle, targets, and antiviral approaches	24
Quantitative measures of within-host viral genetic diversity	24
A structural view of the SARS-CoV-2 virus and its assembly	23
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	23
Editorial Board	22
Non-structural protein 5 (NS5) as a target for antiviral development against established and emergent flaviviruses	22
Virus-host interactions during tick-borne bunyavirus infection	21
Editorial overview: Viral pathogenesis	21
Editorial overview: Virus structure and expression	21
Editorial overview: Special issue on virus structure and expression in current opinion in virology	21
Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses	21
Barriers to hepatitis C virus infection in mice	21
Assembly of the virome in newborn human infants	20
Editorial overview: Viruses and Cancer	20
Oncogenic Animal Herpesviruses	20
Immune responses to human respiratory coronaviruses infection in mouse models	19
Teaching old dogmas new tricks: recent insights into the nuclear import of HIV-1	19
Diagnosis and monitoring of virus-associated cancer using cell-free DNA	19
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications	19